Abstract:
:Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in treatment decisions. We examined 280 newly diagnosed higher-risk elderly MDS patients paired with their physicians. Survey tools included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Control Preference Scale. Overall concordance was 49% for physician perception of patient preferences for involvement in treatment decisions. In 36.4% of comparisons there were minor differences and in 14.6% there were major differences. In 44.7% of the patients preferring a passive role, physicians perceived them as preferring an active or collaborative role. Absence of the patient's request for prognostic information (P=0.001) and judging the patient as having a poor health status (P=0.036) were factors independently associated with the physicians' attitude toward a lower degree of patient involvement in clinical decisions. Agreement on health status was found in 27.5% of cases. Physicians most frequently tended to overestimate health status of patients who reported low-level health status. The value of decision aid-tools in the challenging setting of higher-risk MDS should be investigated to further promote patient-centered care.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Caocci G,Voso MT,Angelucci E,Stauder R,Cottone F,Abel G,Nguyen K,Platzbecker U,Beyne-Rauzy O,Gaidano G,Invernizzi R,Molica S,Criscuolo M,Breccia M,Lübbert M,Sanpaolo G,Buccisano F,Ricco A,Palumbo GA,Niscola P,Zhandoi
10.1016/j.leukres.2015.05.012subject
Has Abstractpub_date
2015-08-01 00:00:00pages
859-65issue
8eissn
0145-2126issn
1873-5835pii
S0145-2126(15)00184-8journal_volume
39pub_type
杂志文章abstract::The role of interferon-gamma (IFN-γ) in Chronic Myelogenous/Myeloid Leukemia (CML) and in the treatment of CML remains unclear; specifically, the effect of IFN-γ on apoptosis. There is reported interplay between IFN-γ and glycogen synthase kinase-3 (GSK-3), a kinase which has been implicated in both cell death and, co...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2020.106464
更新日期:2020-12-01 00:00:00
abstract::Angiogenesis is a complex process controlled by the balance of a large number of regulating factors, the pro- and anti-angiogenic factors. Dysregulation of angiogenesis occurs in various pathologies and is one of the hallmarks for cancer. Recent emphasis on the microenvironment's influence in chronic lymphocytic leuke...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2012.05.021
更新日期:2012-10-01 00:00:00
abstract::We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 year...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/j.leukres.2009.08.010
更新日期:2010-05-01 00:00:00
abstract::Chronic myelogenous leukemia (CML) and 25% of adult onset acute lymphoblastic leukemia (ALL) are associated with the expression of Bcr-Abl, a constitutively activated protein tyrosine kinase. Bcr-Abl associated leukemias are characterized by a high degree of chromosomal and genomic instability. It is unclear if the ph...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(01)00181-3
更新日期:2002-11-01 00:00:00
abstract::Homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high remission rate and provide a survival advantage in acute myeloid leukemia (AML). To investigate whether HAA is an ideal induction regimen for t(8;21)AML, we retrospectively analyzed the data of 140 patients from the las...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2016.02.012
更新日期:2016-05-01 00:00:00
abstract::microRNA profiling of acute myeloid leukemia patient samples identified miR-125a as being decreased. Current literature has investigated miR-125a's role in normal hematopoiesis but not within acute myeloid leukemia. Analysis of the upstream region of miR-125a identified several CpG islands. Both precursor and mature m...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.12.021
更新日期:2014-03-01 00:00:00
abstract::The aberrant changes of tumor suppressor genes (TSGs) are now recognized as an important mechanism contributing to the development of acute myeloid leukemia (AML). CCAAT/enhancer binding protein zeta (C/EBPζ), a candidate TSG, has been found to be involved in cancers including AML. We detected the methylation status o...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2010.10.031
更新日期:2011-07-01 00:00:00
abstract::Murine erythroleukemia (MEL) cells undergo erythroid differentiation in vitro when treated with hexamethylene bisacetamide (HMBA). To identify genes involved in the commitment of MEL cells to differentiate, we screened a cDNA library constructed from HMBA-induced cells by differential hybridization and isolated GTPase...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(02)00231-x
更新日期:2003-07-01 00:00:00
abstract::A variety of genetic and epigenetic abnormalities were characterized over the last years in Hodgkin and Reed-Sternberg (H-RS) cells of classic Hodgkin Lymphoma (cHL). It was speculated that simultaneous inhibition of multiple signalling pathways might be a promising strategy to target this tumor entity. In the present...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.12.013
更新日期:2009-07-01 00:00:00
abstract::The oral bacterium, Aggregatibacter actinomycetemcomitans, produces a leukotoxin (LtxA) that is specific for white blood cells (WBCs) from humans and Old World primates by interacting with lymphocyte function antigen-1 (LFA-1) on susceptible cells. To determine if LtxA could be used as a therapeutic agent for the trea...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.08.022
更新日期:2010-06-01 00:00:00
abstract::Chronic myeloid leukemia (CML) is associated with overexpression of BCR-ABL1, a nonreceptor tyrosine kinase critical for malignant transformation. We investigated whether non-coding microRNAs (miRNAs) targeting BCR-ABL1 mRNA contribute to the pathogenesis of CML. Indeed, miR-30a targeted BCR-ABL1 and was underexpresse...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.12.003
更新日期:2013-03-01 00:00:00
abstract::The classical myeloproliferative neoplasms (MPN) are comparatively uncommon in children and display a degree of mutational naivety if considering the high frequency of known MPN driver events observed in the corresponding adult diseases. Whole exome sequencing has unravelled much of the underlying molecular complexity...
journal_title:Leukemia research
pub_type: 信件
doi:10.1016/j.leukres.2014.06.003
更新日期:2014-08-01 00:00:00
abstract::As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bon...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(01)00134-5
更新日期:2002-04-01 00:00:00
abstract::Forty-three patients were studied to determine whether light chain gene rearrangements may occur in hematopoietic cells not pertaining to the B-lineage. In only one patient, affected by T-cell lymphoblastic lymphoma, one kappa light chain allele was rearranged. Neither at the protein level nor at the RNA level the rea...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90145-j
更新日期:1991-01-01 00:00:00
abstract::Despite high rates of hematologic and cytogenetic responses to imatinib therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of Ph-positive leukemia. The high frequency of BCR-ABL mutations and amplifications represents the high degree of heterogeneity in patients wi...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2003.10.007
更新日期:2004-05-01 00:00:00
abstract::Cases of leukemia associated with Turner syndrome (TS) are rare. Here we report three TS patients with leukemia including one case of T-large granular lymphocyte leukemia (T-LGL), one rare case of coexistence of chronic lymphocytic leukemia (CLL) and idiopathic myelofibrosis (IMF) and one case of a patient with AML-M2...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2007.06.004
更新日期:2008-03-01 00:00:00
abstract::Of 597 cases of acute leukaemia in adults (greater than 16 years) seen at St. Bartholomew's Hospital, London, between May 1973 and January 1982, 412 were diagnosed as AML, 103 as ALL and 58 as Philadelphia chromosome positive blast crisis of CML (13 presenting as acute leukaemia and 45 having a prior chronic phase). T...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(83)90067-x
更新日期:1983-01-01 00:00:00
abstract::To elucidate the biological characteristics of chronic myelogenous leukemia (CML) cells, we observed morphological and functional changes of CML cells during primary long-term culture, in which their morphology changed to that of myofibroblasts with similar molecular characteristics to the parental CML cells including...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2010.09.019
更新日期:2011-05-01 00:00:00
abstract:BACKGROUND:The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-molecule inhibitor of JAK2 that has potential dose-dependent selectivit...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2018.06.014
更新日期:2018-08-01 00:00:00
abstract::Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the inf...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(87)90160-3
更新日期:1987-01-01 00:00:00
abstract::The aim of this study was to describe the presenting features, the frequency and outcome of myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. Twelve MS were seen and the frequency account for only 2% of all acute myeloid leukemia (AML) patients observed in our department in the same...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2004.01.022
更新日期:2004-11-01 00:00:00
abstract::We wish to demonstrate new evidence for the in vivo production of interleukin-3 (IL-3). Syngeneic murine splenocytes were transplanted into lethally irradiated mice. The spleen cells in these transplant mice spontaneously produced IL-3 in cultures, and IL-3-like activity was detected in the serum. Chronological change...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(89)90138-0
更新日期:1989-01-01 00:00:00
abstract::Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2005.10.025
更新日期:2006-07-01 00:00:00
abstract::Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.12.017
更新日期:2013-04-01 00:00:00
abstract::Adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) may be treated either with ongoing systemic chemotherapy or with allogeneic hematopoietic cell transplantation (alloHCT). Despite the presence of phase III trials to support clinical decision-making, we hypothesized that physicians who tr...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.10.021
更新日期:2014-02-01 00:00:00
abstract::The term "refractory anemia" was used in 1937 by Cornelius Parker Rhoads to describe patients whose anemia did not improve after treatment with liver extract or iron salts, and this term has been used to denote patients with certain subtypes of myelodysplastic syndromes (MDS) since the 1976 and 1982 French-American-Br...
journal_title:Leukemia research
pub_type: 历史文章,杂志文章
doi:10.1016/j.leukres.2016.10.007
更新日期:2016-12-01 00:00:00
abstract::Concern has been expressed recently about apparent increases in the incidence of leukaemia amongst young people living in certain geographical areas. We analysed the incidence of childhood leukaemia in South-East Scotland (excluding North-East Fife) from 1970 to 1984. There was a significant geographical variation in ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(86)90091-3
更新日期:1986-01-01 00:00:00
abstract::It has been suggested that imatinib mesylate (IM) influences osteogenesis and bone turnover in treated patients. Here we show that the inhibitory effect of IM on cell multiplication is associated with an increased proportion of spliced osteocalcin (OCNs) in leukemia (HL-60) and osteosarcoma cells (MG-63, U-2 OS), desp...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2007.07.020
更新日期:2008-03-01 00:00:00
abstract::To determine the clinical significance of the T helper 1(Th1)/T helper 2 (Th2) ratio in multiple myeloma, the intracellular IFN-gamma and IL-4 were analyzed by flow cytometry in 56 patients with multiple myeloma. The mean Th1/Th2 ratio of cases in the initial diagnosis phase and the refractory phase were higher than t...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2004.06.003
更新日期:2005-02-01 00:00:00
abstract::We studied 98 female patients in remission (2-240 months) from childhood ALL to determine the clonality status of their hematopoiesis. Thirty-one (31.6%) were heterozygous at the PGK locus for the BstX1 endonuclease restriction site, permitting X-linked clonality assays to be performed. Two patients were in relapse at...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(94)90121-x
更新日期:1994-02-01 00:00:00